FDA accepts NDA for berdazimer gel, 10.3% ,for the treatment of molluscum contagiosum with a PDUFA goal date of 5 January 2024- Novan Inc.
Novan, Inc. announced that the FDA accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum .The Company also received its Prescription Drug User Fee (“PDUFA”) goal date of January 5, 2024.
“ We believe our NCE can provide a much-needed therapeutic option for molluscum patients with the added benefit of being an easily applied, topical, self-administered treatment,” commented Paula Brown Stafford, President and Chief Executive Officer of Novan. “We are thrilled that the FDA determined our application is sufficiently complete, no filing review issues were identified, and that the substantive review process has commenced.”
Ms. Brown Stafford continued, “In early 2022, we acquired marketed dermatology products and a commercial team with product launch expertise. Novan’s commercial infrastructure includes a highly experienced sales and marketing team, supply chain capabilities, market access knowledge, medical affairs experts, and a network of related partners. We believe this not only differentiates Novan in a meaningful way, but also provides the fundamental capabilities to position us for a successful launch and revenue growth following the potential approval of berdazimer gel, 10.3%.”
Related news and insights
Amgen announced new research examining the use of Otezla (apremilast) in psoriatic arthritis, including the Phase IV MOSAIC study and an exploratory analysis of cardiometabolic risk factors, which are commonly elevated in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy
Akebia Therapeutics, Inc. announced that the company received a written response from the Office of New Drugs (OND) of the FDA to Akebia's Formal Dispute Resolution Request (FDRR) regarding the Complete Response Letter (CRL) received in March 2022 for vadadustat
UCB, a global biopharmaceutical company, announced new long-term 52-week data from three Phase III studies BE COMPLETE with its long-term extension study, BE MOBILE 1 and BE MOBILE 2 – evaluating the efficacy and safety profile of bimekizumab, an inhibitor of IL-17F in addition to IL-17A, in adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) and active ankylosing spondylitis (AS), also known as radiographic axSpA (r-axSpA), respectively